Latest News and Press Releases

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between...

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial is evaluating ALRN-6924 as a treatment to...

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily...

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q...

Mr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal...

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or...

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more...